<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02724540</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 01215</org_study_id>
    <nct_id>NCT02724540</nct_id>
  </id_info>
  <brief_title>Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver</brief_title>
  <official_title>Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guerbet</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this trial is to estimate the duration of hepatic progression-free&#xD;
      survival (HPFS) in participants treated with bland embolization (BE), transcatheter arterial&#xD;
      Lipiodol chemoembolization (TACE), and embolization by drug-eluting beads (DEB). The primary&#xD;
      hypothesis is that chemoembolization will be nearly twice as durable as bland embolization;&#xD;
      thatis, the hazard ratio for HPFS will be 1.76 or better.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Abdominal MRI/Triple Phase CT</measure>
    <time_frame>2 years</time_frame>
    <description>Hepatic progression-free interval (H-PFS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>2 years</time_frame>
    <description>Symptom-relief interval and toxicity</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Neuroendocrine Tumor, Malignant</condition>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>Arm 1 - BE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lobar or segmental bland embolization (BE) with microspheres (50-500 microns) to 2-5 heartbeat stasis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 - TACE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lobar or segmental lipiodol conventional transarterial chemoembolization (TACE). Doxorubicin 50 mg dissolved in 10 mL dilute contrast and emulsified with 10-20 cc iodized oil, followed by 50-500 μm microspheres.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 - DEB - CLOSED</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lobar or segmental hepatic chemoembolization with DEBDOX (100-300 or 300-500 micron beads loaded with doxorubicin per manufacturer IFU monthly until entire tumor burden is treated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bland Embolization</intervention_name>
    <description>Lobar or segmental bland embolization with microspheres (50-500 microns) to 2-5 heartbeat stasis</description>
    <arm_group_label>Arm 1 - BE</arm_group_label>
    <other_name>BE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Transarterial chemoembolization</intervention_name>
    <description>Lobar or segmental lipiodol transarterial chemoembolization. Doxorubicin 50 mg dissolved in 10 mL dilute contrast and emulsified with 10-20 cc iodized oil, followed by 50-500 μm microspheres.</description>
    <arm_group_label>Arm 2 - TACE</arm_group_label>
    <other_name>TACE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Drug Eluting Beads Embolization</intervention_name>
    <description>CLOSED - Lobar or segmental hepatic chemoembolization with DEBDOX (100-300 or 300-500 micron beads loaded with doxorubicin per manufacturer IFU.</description>
    <arm_group_label>Arm 3 - DEB - CLOSED</arm_group_label>
    <other_name>DEB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants 18 years and older;&#xD;
&#xD;
          -  Biopsy-proven neuroendocrine tumor.&#xD;
&#xD;
          -  Measurable metastasis to liver with at least one dimension ≥ 1.0 cm.&#xD;
&#xD;
          -  Tumor burden dominant in the liver AND liver tumor burden less than or equal to 70% of&#xD;
             the total liver volume by visual estimate.&#xD;
&#xD;
          -  Not a candidate for surgical resection based on unresectability, anatomy, anesthesia&#xD;
             risk, patient preference.&#xD;
&#xD;
          -  Symptoms uncontrolled by somatostatin analogues OR morphologically progressive tumor&#xD;
             by RECIST 1.1 criteria in the liver OR baseline tumor burden &gt;25% of the liver volume.&#xD;
&#xD;
          -  There must be no plans for the patient to receive other concomitant therapy while on&#xD;
             this protocol treatment (other than somatostatin analogs or bone-strengthening&#xD;
             agents).&#xD;
&#xD;
          -  Performance status 0-2 on Zubrod/ECOG Performance Scale;&#xD;
&#xD;
          -  Serum creatinine &lt; 2.0 mg/dL;&#xD;
&#xD;
          -  Serum Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Serum albumin ≥ 3.0 g/dL&#xD;
&#xD;
          -  Platelet count &gt; 50 thousands/uL (corrected if needed)&#xD;
&#xD;
          -  INR ≤ 1.5 (corrected if needed)&#xD;
&#xD;
          -  All patients must be informed of the investigational nature of this study and must&#xD;
             sign a study specific informed consent in accordance with institutional and federal&#xD;
             guidelines prior to study entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women may not participate due to the embryotoxic effects of&#xD;
             protocol treatment. Women/men of reproductive potential may not participate unless&#xD;
             they have agreed to use an effective contraceptive method.&#xD;
&#xD;
          -  Prior hepatic arterial therapy or hepatic radiation therapy. Prior surgical resection&#xD;
             or ablation of liver metastases is acceptable. Patients must be at least one month&#xD;
             beyond prior chemotherapy, PRRT, ablation or surgery, and have recovered from all&#xD;
             therapy-associated toxicities.&#xD;
&#xD;
          -  Active infection (Symptomatic bacterial and fungal infection - newly diagnosed and/or&#xD;
             requiring treatment);&#xD;
&#xD;
          -  Choledochoenteric anastomosis; transpapillary biliary stent, or sphincterotomy of&#xD;
             duodenal papilla&#xD;
&#xD;
          -  Absolute contraindication to intravenous iodinated contrast (Hx of significant&#xD;
             previous contrast reaction, not mitigated by appropriate pre-medication).&#xD;
&#xD;
          -  Contraindications to arteriography and selective visceral catheterization:&#xD;
&#xD;
               1. severe allergy or intolerance to contrast media, narcotics, sedatives, or&#xD;
                  atropine.&#xD;
&#xD;
               2. bleeding diathesis not correctable by usual forms of therapy.&#xD;
&#xD;
               3. severe peripheral vascular disease precluding catheterization.&#xD;
&#xD;
          -  Contraindications to hepatic artery embolization:&#xD;
&#xD;
               1. portal vein occlusion without hepatopedal collateral flow demonstrated by&#xD;
                  angiography; or portal hypertension with hepatofugal flow.&#xD;
&#xD;
               2. hepatic encephalopathy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael C Soulen, MD, FSIR</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael C Soulen, MD, FSIR</last_name>
    <phone>855-216-0098</phone>
    <email>michael.soulen@uphs.upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Feldman, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicholas Feldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghassan El-Haddad, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ghassan El-Haddad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Wolin</last_name>
    </contact>
    <investigator>
      <last_name>Edward Wolin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etay Ziv</last_name>
    </contact>
    <investigator>
      <last_name>Etay Ziv</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Kolbeck, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Kenneth Kolbeck, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paula Novelli, MD</last_name>
    </contact>
    <investigator>
      <last_name>Paula Novelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rony Avritscher, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rony Avritscher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah B White, MD, MS</last_name>
    </contact>
    <investigator>
      <last_name>Sarah B White, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1191 ABH</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Monaco-Garcia, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ricardo Monaco-Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Dey</last_name>
    </contact>
    <investigator>
      <last_name>Chris Dey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco DeCobelli</last_name>
    </contact>
    <investigator>
      <last_name>Francesco DeCobelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 28, 2016</study_first_submitted>
  <study_first_submitted_qc>March 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2016</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

